Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.42 USD | -3.76% | -4.81% | +9.93% |
Financials (USD)
Sales 2024 * | 34.43M | Sales 2025 * | 19.08M | Capitalization | 461M |
---|---|---|---|---|---|
Net income 2024 * | -89M | Net income 2025 * | -108M | EV / Sales 2024 * | 9.62 x |
Net cash position 2024 * | 130M | Net cash position 2025 * | 10.2M | EV / Sales 2025 * | 23.6 x |
P/E ratio 2024 * |
-5.1
x | P/E ratio 2025 * |
-4.61
x | Employees | 76 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.61% |
Latest transcript on Fulcrum Therapeutics, Inc.
1 day | -3.76% | ||
1 week | -4.81% | ||
Current month | +4.07% | ||
1 month | -0.27% | ||
3 months | -22.71% | ||
6 months | +63.08% | ||
Current year | +9.93% |
Managers | Title | Age | Since |
---|---|---|---|
Alexander Sapir
CEO | Chief Executive Officer | 57 | 23-06-30 |
Alan Musso
DFI | Director of Finance/CFO | 62 | 23-08-06 |
Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Geraghty
BRD | Director/Board Member | 69 | 16-07-18 |
Director/Board Member | 70 | 16-11-30 | |
James Collins
BRD | Director/Board Member | 58 | 16-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% | ||
0.00% | 9 M€ | +9.29% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 7.42 | -3.76% | 379,235 |
24-05-22 | 7.71 | +0.92% | 266,404 |
24-05-21 | 7.64 | -0.78% | 570,501 |
24-05-20 | 7.7 | +1.99% | 451,865 |
24-05-17 | 7.55 | -3.14% | 480,460 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.93% | 461M | |
+64.92% | 62.86B | |
-1.85% | 41.38B | |
+44.76% | 40.38B | |
-8.93% | 27.64B | |
+13.05% | 26.46B | |
-21.96% | 18.9B | |
+4.21% | 12.67B | |
+25.74% | 12.27B | |
+27.42% | 12.07B |
- Stock Market
- Equities
- FULC Stock